Efficacy, Safety, and Immunogenicity of HLX04Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatmentfor Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase IIIStudy
Shukui Qin(Memorial Sloan Kettering Cancer Center), Jiemin Zhao(Liaoning Cancer Hospital & Institute), Xiaoping Qian(Cancer Institute (WIA)), Liangming Zhang(Sun Yat-sen University), Shirong Cai(Sun Yat-sen University), Helong Zhang(Shanghai International Studies University), Guoping Sun(Anhui Medical University), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Hong Zong(First Affiliated Hospital of Zhengzhou University), Jianfeng Zhou(Tongji University), Hongming Pan(Sir Run Run Shaw Hospital), Kehe Chen(The People's Hospital of Guangxi Zhuang Autonomous Region), Jianping Xiong(Nanchang University), Jianwei Lu(Nantong Tumor Hospital), Jin Li(Shanghai Cancer Institute), Bangwei Cao(Capital Medical University), Wei Li(Lanzhou Jiaotong University), Yunfeng Li, Yunfeng Li(Jilin University), Wei Wang(Nanjing Agricultural University), Wei Li(Jilin University), Bai Li(Beijing Union University), Tianshu Liu(Sun Yat-sen University), Haijun Zhong(Zhejiang Cancer Hospital), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Yuan Lin(Capital Medical University), Ying Cheng(First Affiliated Hospital of Xi'an Jiaotong University), Sanyuan Sun(Xuzhou Central Hospital), Yuping Sun(Henan Academy of Agricultural Sciences), Xianli Yin(Central South University), Wenying Kang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanhong Deng(Sun Yat-sen University), Nong Xu(First Affiliated Hospital Zhejiang University), Suxia Luo(Henan Cancer Hospital)
Cited by 29
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA
|Cell Research|2011|1.2k
Surface Chemistry Routes to Modulate the Photoluminescence of Graphene Quantum Dots: From Fluorescence Mechanism to Up‐Conversion Bioimaging Applications
|Advanced Functional Materials|2012|1.1k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k